{
    "ticker": "CWBR",
    "name": "CohBar, Inc.",
    "description": "CohBar, Inc. is a biotechnology company focused on the development of novel therapies for age-related diseases and metabolic disorders. Founded in 2014, CohBar aims to leverage the potential of mitochondrial peptides to address the underlying causes of these conditions. The company has pioneered the discovery of a new class of therapeutic molecules derived from mitochondrial DNA, which have shown promise in preclinical studies for treating diseases such as obesity, diabetes, and neurodegenerative disorders. CohBar's lead product candidates, including CB4211, are designed to enhance metabolic health and improve patient outcomes. With a strong emphasis on innovation, CohBar is committed to advancing its clinical programs and translating scientific discoveries into effective medical treatments. The company collaborates with various research institutions and industry partners to accelerate its drug development efforts, ultimately seeking to improve the quality of life for patients worldwide. With a focus on addressing significant unmet medical needs, CohBar is at the forefront of a new era in therapeutic development, harnessing the power of mitochondrial biology to create groundbreaking solutions for chronic diseases.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Menlo Park, California, USA",
    "founded": "2014",
    "website": "https://www.cohbar.com",
    "ceo": "Joseph A. M. D. R. C. C. A. D. R. C. A. D. R. C. A. D. R. C. A. D. R. C.",
    "social_media": {
        "twitter": "https://twitter.com/CohBarInc",
        "linkedin": "https://www.linkedin.com/company/cohbar/"
    },
    "investor_relations": "https://ir.cohbar.com",
    "key_executives": [
        {
            "name": "Joseph A. C. M. D.",
            "position": "CEO"
        },
        {
            "name": "David M. C. D.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutic Candidates",
            "products": [
                "CB4211",
                "CB5138-3"
            ]
        }
    ],
    "seo": {
        "meta_title": "CohBar, Inc. | Innovative Therapies for Age-Related Diseases",
        "meta_description": "Explore CohBar, Inc., a biotechnology company focused on developing breakthrough therapies for age-related diseases and metabolic disorders using mitochondrial peptides.",
        "keywords": [
            "CohBar",
            "Biotechnology",
            "Mitochondrial Peptides",
            "Age-Related Diseases",
            "Metabolic Disorders"
        ]
    },
    "faq": [
        {
            "question": "What does CohBar focus on?",
            "answer": "CohBar focuses on developing novel therapies for age-related diseases and metabolic disorders using mitochondrial peptides."
        },
        {
            "question": "Who is the CEO of CohBar?",
            "answer": "Joseph A. C. M. D. is the CEO of CohBar, Inc."
        },
        {
            "question": "Where is CohBar headquartered?",
            "answer": "CohBar is headquartered in Menlo Park, California, USA."
        },
        {
            "question": "What are CohBar's lead product candidates?",
            "answer": "CohBar's lead product candidates include CB4211 and CB5138-3."
        },
        {
            "question": "When was CohBar founded?",
            "answer": "CohBar was founded in 2014."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "VRTX"
    ],
    "related_stocks": [
        "GILD",
        "BMY",
        "MRNA",
        "NVAX"
    ]
}